BioNexus to Build AI Applications for Malaysian Healthcare Under Exclusive CogniAI Licence
The agreement requires no cash payment for the licence, but contemplates share issuance and royalties on collected technology receipts.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
BioNexus Gene Lab (Nasdaq: BGLC) signed an agreement with Ruanyun Edai Technology for an exclusive Malaysian healthcare licence to CogniAI. BioNexus plans to develop applications for public healthcare digitalization, but has no government contract. The licence would run for ten years from closing, with two five-year renewal options; exclusivity is subject to milestone, cure and termination provisions.
At closing, BioNexus would issue 410,000 common shares for stated US$3.5 million licence consideration and another 150,000 shares for 500,000 RYET ordinary shares. No cash payment is required. RYET would receive 10% of defined technology receipts collected. Closing remains subject to technology delivery, written acceptance, satisfactory due diligence and required approvals. Delivery is due December 4, 2026; either non-defaulting party may terminate if closing has not occurred by March 31, 2027, unless extended.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Major point. Forward-looking: it has not happened yet and may not happen.Exclusive Malaysian healthcare licence would last ten years from closing, with two five-year renewal options.
- Minor pointLicence consideration requires no cash payment or market-value guarantee.
- Minor point. Forward-looking: it has not happened yet and may not happen.Share exchange would give BioNexus 500,000 RYET ordinary shares at closing.
- Minor point. Forward-looking: it has not happened yet and may not happen.Platform rights would permit hosting, adaptation, integration and sublicensing, with BioNexus retaining ownership of developed applications.
- Minor point. Forward-looking: it has not happened yet and may not happen.BioNexus plans CogniAI-based healthcare applications and discussions with government digitalization initiatives.
2 minor points
- Minor point. Forward-looking: it has not happened yet and may not happen.Industry expansion rights allow BioNexus to add other Malaysian industries by written notice.
- Minor pointRoyalty terms include no minimum royalty or annual platform fee; testing, clinical fees and separately identifiable services are excluded.
Negative
- Major point. Forward-looking: it has not happened yet and may not happen.Proposed issuance of 560,000 common shares would dilute holders, including 410,000 for stated US$3.5 million licence consideration. 96% of market cap
- Minor point. Forward-looking: it has not happened yet and may not happen.Royalty obligation would equal 10% of defined technology receipts actually collected.
- Minor pointClosing depends on technology delivery, written acceptance, satisfactory due diligence and required approvals.
- Minor pointClosing deadline permits either non-defaulting party to terminate after March 31, 2027, unless extended.
- Minor pointHealthcare exclusivity remains subject to milestone, cure and termination provisions.
2 minor points
- Minor pointAdded-industry exclusivity requires a customer contract within twelve months; additional RYET work requires a separate project agreement.
- Minor pointBioNexus has no government contract; public-sector work depends on government procurement.
News Explained
The additional rights put application ownership with BioNexus and allow expansion beyond healthcare, but broader exclusivity depends on a timely customer contract.
The signed agreement remains pending closing; if completed, it would give BioNexus rights to host, adapt, integrate, build branded applications with, and sublicense CogniAI, while BioNexus would own the applications it develops.
BioNexus may also add other Malaysian industries by written notice, but exclusivity in each added industry continues only if a customer contract is signed within twelve months; further work with RYET would require a separate project agreement.
Key Figures
- Healthcare digitalization allocation
- RM1 billion
- Malaysian public healthcare programme
- Programme coverage
- 150 hospitals and more than 2,000 health clinics
- Malaysian public healthcare digitalization programme
- Licence term
- 10 years + two 5-year renewal options
- Exclusive Malaysian healthcare licence; renewals are BGLC options
- Licence consideration
- 410,000 common shares for US$3.5 million
- Stated contractual amount; payable at closing in shares
- Share exchange
- 150,000 BGLC shares for 500,000 RYET ordinary shares
- Additional exchange under the agreement
- Royalty
- 10%
- Of defined technology receipts actually collected; no minimum royalty or annual platform fee
- Technology delivery deadline
- December 4, 2026
- RYET delivery deadline; BGLC acceptance testing follows
- Closing termination date
- March 31, 2027
- Either non-defaulting party may terminate if closing has not occurred, unless extended
Previous AI Reports
-
RYET disclosed the same exclusive Malaysian healthcare licence, share consideration, royalty, and conditional closing.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
sublicense financial
acceptance testing technical
unaudited financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
Licence of up to 20 years, payable in shares, as Malaysia commits RM1 billion to digitalizing public healthcare
KUALA LUMPUR, Malaysia, Oct. 07, 2026 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (Nasdaq: BGLC) ("Company" or "BGLC") today announced plans to build AI applications for Malaysian healthcare, following the signing of a definitive agreement with Ruanyun Edai Technology Inc. (Nasdaq: RYET) on October 5, 2026 for an exclusive Malaysian healthcare licence to RYET's CogniAI artificial intelligence platform. BGLC's first target is Malaysia's public healthcare digitalization programme, which covers 150 hospitals and more than 2,000 health clinics. Closing and the contemplated share issuances remain pending.
"With CogniAI we would not be starting from a blank page," said Sam Tan, Chief Executive Officer of BioNexus Gene Lab Corp. "The platform exists and is in commercial use, and our job is to build the applications around it. Malaysia is putting real money into taking public healthcare records digital, and that is where we intend to go first."
The opportunity
In August 2026, the Malaysian government raised its allocation for public healthcare digitalization to RM1 billion, covering electronic medical records and connectivity at 150 hospitals and more than 2,000 health clinics. The Ministry of Health has said public hospitals and health facilities nationwide are to be equipped with electronic medical records by 2029. Its facilities recorded 68.2 million patient arrivals in 2023, according to ministry data tabled in Parliament in 2025.
BGLC intends to offer CogniAI-based applications that complement those systems by bringing existing paper and scanned records into digital form. BGLC has not been awarded any government contract, and any public-sector work would depend on government procurement.
More broadly, a November 2024 report by Grand View Research projects the global intelligent document processing market to reach approximately US
A platform already in commercial use
CogniAI is RYET's AI platform for document intelligence. It recognizes, classifies and extracts information from documents and records. In June 2026, RYET reported approximately US
"BioNexus knows the Malaysian market and its healthcare providers, and that local knowledge is what turns a platform into working applications," said Maggie Fu, Chief Executive Officer of Ruanyun Edai Technology Inc. "We built CogniAI to read and organize records at scale, and we look forward to supporting BioNexus as it takes the platform into healthcare."
At closing, BGLC would receive rights to host, adapt and integrate the platform, build and brand applications using it, and sublicense the technology to customers and implementation partners during the prescribed term. BGLC would lead local implementation and customer relationships, and it retains ownership of the applications it develops. Personal data must be hosted in Malaysia, with no RYET Group access from outside the country.
The licence adds a third element to the AI and technology strategy BGLC has been building. The first two are its investments, in Ascension Innovation Sdn. Bhd. in August 2024 and in Fidelion Diagnostics Pte. Ltd. in November 2025, when it also obtained exclusive ASEAN rights to the VitaGuard™ minimal residual disease platform, and its own GeneMatrix Systems software development.
Key terms of the RYET agreement
- Licence. Exclusive for healthcare in Malaysia for ten years from closing, with two five-year renewal options for BGLC. Exclusivity is subject to the agreement's milestone, cure and termination provisions.
- Other industries. BGLC may add other Malaysian industries by written notice. Exclusivity in an added industry continues only if a customer contract is signed within twelve months. Additional RYET work would require a separate project agreement.
- Consideration. At closing, BGLC will issue 410,000 common shares for the stated US
$3.5 million licence consideration, a contractual amount and not a statement of fair value. There is no cash payment or market-value guarantee. - Share exchange. BGLC will issue another 150,000 common shares in exchange for 500,000 RYET ordinary shares, for 560,000 shares in total.
- Royalty to RYET.
10% of defined technology receipts actually collected, with no minimum royalty or annual platform fee. Testing and clinical fees and separately identifiable services are excluded. - Closing. Subject to technology delivery and BGLC's written acceptance, satisfactory due diligence, and required approvals. Either non-defaulting party may terminate if closing has not occurred by March 31, 2027, unless extended.
Next steps
RYET is required to deliver the technology by December 4, 2026, which is 60 days after signing. BGLC will then carry out acceptance testing. In parallel, BGLC plans to begin discussions on offering CogniAI-based applications to government digitalization initiatives.
"We structured the agreement to keep cash in the business," Mr. Tan said. "RYET is taking its licence consideration in our shares and a royalty only on what we collect, so it does well only if we do. The next step is practical. We take delivery, test the technology, and take it to the people running Malaysia's healthcare digitalization."
About BioNexus Gene Lab Corp.
BioNexus Gene Lab Corp. (Nasdaq: BGLC) is a technology-focused company operating across biotechnology, precision diagnostics and specialty materials. Through its subsidiaries, investments and licensing arrangements, the Company is developing new healthcare and life-science businesses alongside its established operations.
For more information, visit www.bionexusgenelab.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These include statements about BGLC's AI and healthcare strategy, including anticipated connections with its investments and VitaGuard work; plans to develop and commercialize its own AI applications; the expected contribution of CogniAI; GeneMatrix report-access and companion development; technology delivery, acceptance testing, licence activation and closing; plans to offer applications to government digitalization initiatives and the outcome of any public procurement; market size and growth projections; additional-industry opportunities; customer adoption; future royalties; and the benefits of the reciprocal share investment. Words such as "will," "would," "plan," "intend," "may," "expect" and similar expressions identify forward-looking statements.
Actual results may differ materially because of technology delivery and acceptance; ownership and third-party rights; any required PRC technology-export approvals; performance on English- and Malay-language records and integration environments; data protection, cybersecurity and healthcare regulation; development readiness; implementation resources and funding; the parties' financial condition, including going-concern uncertainties disclosed in their filings; customer demand, government budgets, priorities and procurement outcomes, and competition; the accuracy of third-party market estimates, which BGLC has not independently verified; share-price volatility, dilution and investment impairment; and accounting judgments. The agreement does not assure closing, customer contracts, revenue, profitability or clinical outcomes. Additional risks appear in BGLC's latest Form 10-K, subsequent Forms 10-Q and other SEC filings. Forward-looking statements speak only as of the date made. BGLC undertakes no obligation to update them except as required by law.
Investor Relations and Corporate Communications
BioNexus Gene Lab Corp.
ir@bionexusgenelab.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
When must RYET deliver CogniAI to BioNexus?
RYET must deliver the technology by December 4, 2026, after which BioNexus will conduct acceptance testing. Closing requires technology delivery and BioNexus's written acceptance, satisfactory due diligence and required approvals. Either non-defaulting party may terminate if closing has not occurred by March 31, 2027, unless extended.
Where must personal data be hosted under BioNexus's CogniAI agreement?
Personal data must be hosted in Malaysia, with no RYET Group access from outside the country.
Which receipts are excluded from BioNexus's CogniAI royalty?
Testing and clinical fees and separately identifiable services are excluded from the royalty base. RYET would receive 10% of defined technology receipts actually collected, with no minimum royalty or annual platform fee.
Can BioNexus expand its CogniAI licence beyond Malaysian healthcare?
BioNexus may add other Malaysian industries by written notice. Exclusivity in an added industry continues only if a customer contract is signed within twelve months. Additional RYET work would require a separate project agreement.